Copeptin level and copeptin response to percutaneous balloon mitral valvuloplasty in mitral stenosis

Cardiology

Volumn 120, Issue 4, 2012, Pages 221-226

  Günebakmaz, Özgür ^a   Celik, Ahmet ^b   Inanc, M Tugrul ^c   Duran, Mustafa ^b   Karakaya, Ekrem ^d   Tulmac, Murat ^e   Akpek, Mahmut ^c   Sarli, Bahadir ^b   Ergin, Ali ^c   Topsakal, Ramazan ^c  

^a Kastamonu Munif Islamoglu State Hospital   (Turkey)

^b Elazig Education and Research Hospital ^*  (Turkey)

^c ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^d Kir ehir State Hospital   (Turkey)

^e KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Copeptin; Mitral stenosis; Percutaneous balloon mitral valvuloplasty

Indexed keywords

BIOLOGICAL MARKER; PROTEIN COPEPTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; MALE; MITRAL VALVE; MITRAL VALVE REPAIR; MITRAL VALVE STENOSIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; TRANSLUMINAL VALVULOPLASTY;

ADULT; BALLOON DILATION; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GLYCOPEPTIDES; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS;

EID: 84856902766     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000335888     Document Type: Article

References (33)

1. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force: 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523-e661.
2. Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoto N: Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 1984; 87: 394-402. (Pubitemid 14160444)
3. Nobuyoshi M, Arita T, Shirai S, Hamasaki N, Yokoi H, Iwabuchi M, Yasumoto H, Nosaka H: Percutaneous balloon mitral valvuloplasty: a review. Circulation 2009; 119: 211-219.
4. Itoi K, Jiang YQ, Iwasaki Y, Watson SJ: Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol 2004; 16: 348-355. (Pubitemid 38618652)
5. Struck J, Morgenthaler NG, Bergmann A: Copeptin, a stable peptide derived from the precursor, is elevated in serum of sepsis patients. Peptides 2005; 26: 2500-2504. (Pubitemid 41676723)
6. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R: Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008; 52: 266-272. (Pubitemid 351957847)
7. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF: Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988; 60: 299-308.
8. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA: Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167-184.
9. Kircher BJ, Himelman RB, Schiller NB: Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 1990; 66: 493-496. (Pubitemid 20259386)
10. Sellers RD, Levy MJ, Amplatz K, Lillehei CW: Left retrograde cardioangiography in acquired cardiac disease: technic, indications and interpretations in 700 cases. Am J Cardiol 1964; 14: 437-447.
11. Narin N, Kütükçüler N, Ozyürek R, Bakiler AR, Parlar A, Arcasoy M: Lymphocyte subsets and plasma IL-1 alpha, IL-2, and TNFalpha concentrations in acute rheumatic fever and chronic rheumatic heart disease. Clin Immunol Immunopathol 1995; 77: 172-176.
12. Morris K, Mohan C, Wahi PL, Anand IS, Ganguly NK: Enhancement of IL-1, IL-2 production and IL-2 receptor generation in patients with acute rheumatic fever and active rheumatic heart disease; a prospective study. Clin Exp Immunol 1993; 91: 429-436. (Pubitemid 23074148)
13. Cagli KE, Aras D, Topaloglu S, Geyik B, Ayaz S, Cagirci G, Kisacik HL, Korkmaz S: Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty. Heart Vessels 2010;25: 131-137.
14. Ileri M, Büyükaşik Y, Ileri NS, Haznedaroglu IC, Göksel S, Kirazli S, Dündar S: Activation of blood coagulation in patients with mitral stenosis and sinus rhythm. Am J Cardiol 1998; 81: 795-797. (Pubitemid 28146464)
15. Marín F, Roldán V, Monmeneu JV, Bodí V, Fernández C, de Burgos FG, Marco P, Sogorb F: Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. Am J Cardiol 1999; 84: 862-864. (Pubitemid 29469802)
16. Topaloglu S, Aras D, Ergun K, Geyik B, Ayaz S, Cay S, Cagirci G, Tufekcioglu O, Korkmaz S: Plasma level of soluble P-selectin in patients with rheumatic mitral stenosis and sinus rhythm undergoing percutaneous mitral balloon valvuloplasty. J Thromb Thrombolysis 2007;23:199-204. (Pubitemid 46564120)
17. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH: Atrial secretion of Btype natriuretic peptide. Eur Heart J 2006; 27: 1648-1650. (Pubitemid 44025348)
18. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, Ohnishi M, Sawaki M, Fujii M, Horie H, Sugimoto Y, Kinoshita M: Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20: 1799-1807.
19. Iltumur K, Karabulut A, Yokus B, Yavuzkir M, Taskesen T, Toprak N: N-terminal proBNP plasma levels correlate with severity of mitral stenosis. J Heart Valve Dis 2005; 14: 735-741.
20. Chadha DS, Karthikeyan G, Goel K, Malani SK, Seth S, Singh S, Dhall A, Bhargava B: Nterminal pro-BNP plasma levels before and after percutaneous transvenous mitral commissurotomy for mitral stenosis. Int J Cardiol 2010; 144: 238-240.
21. Ramakrishnan S, Agarwal A, Singh S, Karthikeyan G, Seth S, Narang R, Bhargava B: NT-pro-BNP levels as a marker of success of percutaneous transvenous mitral commissurotomy. Indian Heart J 2010; 62: 35-38.
22. Katan M, Muller B, Christ-Crain M: Copeptin: a new and promising diagnostic and prognostic marker. Crit Care 2008; 12: 117.
23. Jarai R, Mahla E, Perkmann T, Jarai R, Archan S, Tentzeris I, Huber K, Metzler H: Usefulness of pre-operative copeptin concentrations to predict post-operative outcome after major vascular surgery. Am J Cardiol 2011; 108: 1188-1195.
24. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119. (Pubitemid 43032474)
25. Antonescu-Turcu AL, Tomic R: C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med 2009; 15: 120-125.
26. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M: Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28: 219-226. (Pubitemid 47220835)
27. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton- Cheh C, Melander O: Plasma copeptin and the risk of diabetes mellitus. Circulation 2010; 121: 2102-2108.
28. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C: Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009; 54: 60-68.
29. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007; 115: 2103-2110. (Pubitemid 46659061)
30. Narayan H, Dhillon OS, Quinn PA, Struck J, Squire IB, Davies JE, Ng LL: C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: Leicester Acute Myocardial Infarction Peptide II (LAMP II) study. Clin Sci (Lond) 2011; 121: 79-89.
31. Oghlakian G, Klapholz M: Vasopressin and vasopressin receptor antagonists in heart failure. Cardiol Rev 2009; 17: 10-15.
32. Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheorghiade M, Adams KF Jr: Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18. (Pubitemid 36851295)
33. Jin HK, Yang RH, Chen YF, Thornton RM, Jackson RM, Oparil S: Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia. J Appl Physiol 1989; 66: 151-160. (Pubitemid 19056070)